SLC12A3: A Potential Drug Target for Skin Diseases (G6559)

Target Name: SLC12A3

NCBI ID: G6559

SLC12A3

SLC12A3: A Potential Drug Target for Skin Diseases

SLC12A3 (Sunlight-sensitive cDNA gene 12.0) is a gene that has been identified as a potential drug target or biomarker for the treatment of skin diseases, including skin cancer. The SLC12A3 gene is located on chromosome 12 and encodes a protein that is involved in the process of intracellular signaling, specifically the regulation of the cytoskeleton.

SLC12A3 has been shown to be aberrantly expressed in a variety of skin diseases, including skin cancer, psoriasis, and dermatitis. In addition, studies have also shown that SLC12A3 is involved in the regulation of cell growth, differentiation, and survival.

One of the potential reasons why SLC12A3 has been identified as a drug target is because of its involvement in the regulation of the cytoskeleton. The cytoskeleton is the structure that gives shape to the cell and is involved in many important cellular processes, including cell division, migration, and signaling.

SLC12A3 has been shown to be involved in the regulation of cytoskeleton structure and function. For example, studies have shown that SLC12A3 is involved in the regulation of microtubule dynamics and stability, as well as the assembly and disassembly of microtubules.

In addition, SLC12A3 has also been shown to be involved in the regulation of actinin cytoskeleton, which is a protein that is involved in the regulation of cell shape and movement.

Another potential reason why SLC12A3 has been identified as a drug target is because of its involvement in the regulation of cell survival. Studies have shown that SLC12A3 is involved in the regulation of cell survival and that aberrantly expressed levels of SLC12A3 have been associated with poor prognosis in skin diseases.

In addition, SLC12A3 has also been shown to be involved in the regulation of cell proliferation, which is the process by which cells grow and divide. Studies have shown that SLC12A3 is involved in the regulation of cell proliferation and that aberrantly expressed levels of SLC12A3 have been associated with increased cell proliferation and the development of cancer.

In conclusion, SLC12A3 is a gene that has been identified as a potential drug target or biomarker for the treatment of skin diseases. Its involvement in the regulation of the cytoskeleton and cell survival makes it a promising target for the development of new treatments for skin diseases. Further research is needed to fully understand the role of SLC12A3 in skin disease and to develop safe and effective treatments.

Protein Name: Solute Carrier Family 12 Member 3

Functions: Electroneutral sodium and chloride ion cotransporter. In kidney distal convoluted tubules, key mediator of sodium and chloride reabsorption (PubMed:21613606, PubMed:22009145). Receptor for the pro-inflammatory cytokine IL18. Contributes to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2. May act either independently of IL18R1, or in a complex with IL18R1 (By similarity)

The "SLC12A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC12A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets